EUCTR2009-017781-23-AT进行中（未招募）不适用
An Open Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult Population - ADULT SAFETY STUDY OF 2009/2010 SEASONAL INFLUENZA VACCINE.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject is 18 to 59 years of age , inclusive, at the time of screening;
- •Subject has given written informed consent prior to study entry;
- •Subject is generally healthy , as determined by the investigator’s clinical judgment through collection of medical history and performance of a physical examination, such that the investigator would not hesitate to provide routine influenza immunization to the subject in the course of routine medical practice;
- •Subject agrees to keep a daily record of symptoms for the duration of the study;
- •If female of childbearing potential, subject presents with a negative urine pregnancy test immediately prior to vaccination on Study Day 1 and agrees to employ adequate birth control measures for the duration of the study;
- •Subject is willing and able to comply with the requirements of the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subject has a history of severe allergic reaction or anaphylaxis;
- •Subject has an oral temperature of =37.5°C on the day of vaccination in this study;
- •Subject has a dermatologic condition or tattoos, which may interfere with injection site reaction rating;
- •Subject has received a live vaccine within 4 weeks or an inactivated or subunit vaccine within 2 weeks of study entry;
- •Subject has been vaccinated with seasonal influenza vaccine for the 2009/2010 season.
- •Subject currently has or had a history of a significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorder ;
- •Subject has any inherited or acquired immunodeficiency;
- •Subject has a disease or is currently undergoing a form of treatment or was undergoing a form of treatment within 30 days prior to study entry that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled (>800 µg/day of beclomethasone dipropionate or equivalent) corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs;
- •Subject has a functional or surgical asplenia;
- •Subject has a known or suspected problem with alcohol or drug abuse;
- •Subject is a member of the team conducting this study or is in a dependent relationship with one of the study team members. Dependent relationships include close relatives (ie., children, partner/spouse, siblings, parents) as well as employees of the investigator or site personnel conducting the study;
- •If female, subject is pregnant or lactating at the time of study enrollment;
- •Subject has participated in another clinical study involving an IP or investigational device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
研究者
相似试验
进行中（未招募）
不适用
An Open Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult Population - Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine.To verify the safety and immunogenicity of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2009/2010 season, manufactured according to the standard manufacturing process using a fixed Trition-X concentration during the splitting process (Formula A) (Cohort 1) and a modified manufacturing process control using a fixed protein to Triton X-100 ratio during the splitting process of the H3N2 and the B strain (Formulation B) (Cohort 2)MedDRA version: 12.1Level: LLTClassification code 10022000Term: InfluenzaEUCTR2009-017781-23-BEBaxter Innovations GmbH220
进行中（未招募）
不适用
An Open-Label Phase III Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as well as in Specified Risk Groups - Phase III Study of a H5N1 Vaccine in Adults, Elderlys, and Specified Risk Groups.H5N1 vaccination in healthy subjects (adult and elderly population) and in specified risk groups (chronically ill, transplant and HIV patients).EUCTR2008-000558-11-FIBaxter Innovations GmbH3,560
进行中（未招募）
不适用
An Open-Label Phase III Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as well as in Specified Risk Groups - Phase III Study of a H5N1 Vaccine in Adults, Elderlys, and Specified Risk Groups.EUCTR2008-000558-11-NLBaxter Innovations GmbH3,560
进行中（未招募）
不适用
An Open-Label Phase III Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as well as in Specified Risk Groups - Phase III Study of a H5N1 Vaccine in Adults, Elderlys, and Specified Risk Groups.EUCTR2008-000558-11-LVBaxter AG3,560
进行中（未招募）
1 期
An Open-Label Phase III Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as well as in Specified Risk Groups - Phase III Study of a H5N1 Vaccine in Adults, Elderlys, and Specified Risk Groups.EUCTR2008-000558-11-ATBaxter Innovations GmbH